Research Coverage on Small and Micro-Cap Companies, Zacks Small Cap Research

Zacks Small Cap Research

Research Coverage on Small and Micro-Cap Companies

Zacks Small Cap Research provides research coverage on small- and micro-cap companies that are “under-followed” or “under-valued” by Wall Street. We produce high quality equity research for the institutional and retail investor on microcap firms we believe are well positioned for future growth. The Zacks SCR analyst team has an average of 20 years of experience in investment research. We conduct significant due diligence in an effort to maintain the highest quality small-cap universe.

Equity Bottom-Up

<ul><li>EVAX is a clinical stage company that has proprietary AI models designed to more efficiently and more accurately target much-needed treatments.</li><li>The company has two streams of possible revenue: from the treatments themselves and from the licensing of AI technology.</li><li> The company announced its AI technology has identified a new novel vaccine target to combat a major bacterial infection impacting hundreds of millions of people around the world.</li></ul>

EVAX is a clinical stage company that has proprietary AI models designed to more efficiently and more accurately target much-needed treatments.The company has two streams of possible revenue: from the treatments themselves and from the licensing of AI technology. The company announced its AI technology has identified a new novel vaccine target to combat a major bacterial infection impacting hundreds of millions of people around the world.

<ul><li>EVAX is a clinical stage company that has proprietary AI models designed to more efficiently and more accurately target much-needed treatments.</li><li>The company has two streams of possible revenue: from the treatments themselves and from the licensing of AI technology.</li><li> The company announced it received a grant to develop a new and unique vaccine with the goal of eradicating polio.</li></ul>

EVAX is a clinical stage company that has proprietary AI models designed to more efficiently and more accurately target much-needed treatments.The company has two streams of possible revenue: from the treatments themselves and from the licensing of AI technology. The company announced it received a grant to develop a new and unique vaccine with the goal of eradicating polio.

<ul><li>EVAX is a clinical stage company that has proprietary AI models designed to more efficiently and more accurately target much-needed treatments.</li><li>The company has two streams of possible revenue: from the treatments themselves and from the licensing of AI technology.</li><li> The company announced 1Q2025 financial results and highlighted many of the advances made in recent months.</li></ul>

EVAX is a clinical stage company that has proprietary AI models designed to more efficiently and more accurately target much-needed treatments.The company has two streams of possible revenue: from the treatments themselves and from the licensing of AI technology. The company announced 1Q2025 financial results and highlighted many of the advances made in recent months.

EVAX:  1Q Results Show Potential and Good Cash

<ul><li>EVAX is a clinical stage company that has proprietary AI models designed to more efficiently and more accurately target much-needed treatments.</li><li>The company has two streams of possible revenue: from the treatments themselves and from the licensing of AI technology.</li><li> The company announced that data on its cancer vaccine showed strong and encouraging results.</li></ul>

EVAX is a clinical stage company that has proprietary AI models designed to more efficiently and more accurately target much-needed treatments.The company has two streams of possible revenue: from the treatments themselves and from the licensing of AI technology. The company announced that data on its cancer vaccine showed strong and encouraging results.

EVAX:  Cancer Vaccine Shows Great Results

<ul><li>EVAX is a clinical stage company that has proprietary AI models designed to more efficiently and more accurately target much-needed treatments.</li><li>The company has two streams of possible revenue: from the treatments themselves and from the licensing of AI technology.</li><li> The company released its full-year 2024 results and updated investors on the tremendous progress made.</li></ul>

EVAX is a clinical stage company that has proprietary AI models designed to more efficiently and more accurately target much-needed treatments.The company has two streams of possible revenue: from the treatments themselves and from the licensing of AI technology. The company released its full-year 2024 results and updated investors on the tremendous progress made.

EVAX:  Company Lays Out Ambitious 2025 Plan

Denmark

Evaxion Biotech A/S operates as a biotechnology company. The Company develops AI-immunology platform for decoding human immune system to discover and develop immunotherapies for cancer and infectious diseases treatment. Evaxion Biotech serves patients in Denmark.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Evaxion Biotech A/S (EVAX US)

EVAX: New Vaccine Added to Pipeline

EVAX is a clinical stage company that has proprietary AI models designed to more efficiently and more accurately target much-needed...

Zacks Small Cap Research

EVAX: Grant For Polio Vaccine Announced

EVAX is a clinical stage company that has proprietary AI models designed to more efficiently and more accurately target much-needed...

Zacks Small Cap Research

EVAX: 1Q Results Show Potential and Good Cash

EVAX is a clinical stage company that has proprietary AI models designed to more efficiently and more accurately target much-needed...

Zacks Small Cap Research

EVAX: Cancer Vaccine Shows Great Results

EVAX is a clinical stage company that has proprietary AI models designed to more efficiently and more accurately target much-needed...

Zacks Small Cap Research

EVAX: Company Lays Out Ambitious 2025 Plan

EVAX is a clinical stage company that has proprietary AI models designed to more efficiently and more accurately target much-needed...

Zacks Small Cap Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)